Still un­der clin­i­cal hold, Ful­crum locks in sea­soned com­mer­cial leader as CEO

Ful­crum Ther­a­peu­tics has re­cruit­ed a new chief ex­ec­u­tive well versed in the mar­ket­ing world amid man­age­ment up­heaval, a full clin­i­cal hold for its sick­le cell pro­gram and a Phase III for a dif­fer­ent rare dis­ease drug.

Alex Sapir, who served as CEO at Re­Vi­ral un­til Pfiz­er bought it last April, will re­place Robert Gould as Ful­crum CEO on Ju­ly 1. But that’s not the on­ly change hap­pen­ing at the top: In its quar­ter­ly re­port, Ful­crum al­so re­vealed that CFO Es­ther Ra­javelu has re­signed, al­though she will re­main in a con­sult­ing role.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN